Shilpa Medicare Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shilpa Medicare announced Q1 FY26 (ended June 30, 2025) unaudited results. Standalone revenue from operations dipped ~3.8% YoY to Rs 9,243 lakhs, with net profit at Rs 2,070 lakhs (down ~26% YoY), aided by a Rs 1,138 lakh tax reversal from the merger of INM Technologies. Consolidated revenue grew ~9.9% YoY to Rs 32,146 lakhs, while consolidated PAT surged ~233% to Rs 4,689 lakhs (EPS Rs 4.79 vs Rs 1.46). The company booked an exceptional loss of Rs 518 lakhs on standalone basis, mainly for impairment of advances/investments in foreign subsidiaries (Koanna entities, Indo Biotech Malaysia). The board declared a 1:1 bonus issue (record date September 26, 2025), approved promoter reclassification for Suraj Kumar Inani and Priya Inani to public category, and made multiple director appointments/re-appointments. Auditor BNPS and Associates gave an unmodified review opinion. Prior period figures were restated to reflect the INM Technologies merger.
The 1:1 bonus issue and sharp consolidated PAT growth are positive for shareholders, though standalone revenue decline and recurring foreign-subsidiary impairments are red flags. Tax reversals flattered standalone earnings, so underlying profitability needs scrutiny. Watch for stock reaction to the bonus and the volatility around promoter reclassification.